Search results for "Neoadjuvant"

showing 10 items of 161 documents

Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer

2023

Objective: To identify the best method among the radiologic, laparoscopic and laparotomic scoring assessment to predict the outcomes of cytoreductive surgery in patients with advanced ovarian cancer (AOC). Methods: Patients with AOC who underwent pre-operative computed tomography (CT) scan, laparoscopic evaluation, and cytoreductive surgery between August 2016 and February 2021 were retrospectively reviewed. Predictive Index (PI) score and Peritoneal Cancer Index (PCI) scores were used to estimate the tumor load and predict the residual disease in the primary debulking surgery (PDS) and interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) groups. Concordance percentages we…

Predictive index scoreCancer ResearchOncologyOvarian cancerPrediction modelCytoreductive surgeryPrimary debulking surgery.Interval debulking surgeryNeoadjuvant chemotherapyPeritoneal cancer index scoreSettore MED/40 - Ginecologia E Ostetriciaovarian cancer; cytoreductive surgery; prediction model; predictive index score; peritoneal cancer index score; primary debulking surgery; interval debulking surgery; neoadjuvant chemotherapyCancers
researchProduct

The use of video-assisted thoracic surgery in the management of Pancoast tumours

2010

We describe our experience using video-assisted thoracic surgery (VATS) as an adjunct to the surgical management of Pancoast tumors. Between March 2004 and November 2009, 13 patients with Pancoast tumors were included in this study. Surgery was performed by positioning the patient to allow either an anterior or a posterior thoracotomy. VATS was employed to explore the pleural cavity, to optimize the surgical access and as an assistance during surgical resection. Three patients with pleural carcinosis at thoracoscopy did not undergo further surgery. Seven lobectomies and three wedge resections were performed with an en bloc chest-wall resection and mediastinal lymphadenectomy. The surgical a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyTime FactorsCarcinosismedicine.medical_treatmentBlood Loss SurgicalGeneral thoracic surgerySuperior sulcus tumorsPatient PositioningGeneral thoracic surgery; Lung cancer; Superior sulcus tumorsPancoast tumorPneumonectomymedicineThoracoscopyHumansThoracotomyPneumonectomyAgedmedicine.diagnostic_testbusiness.industryThoracic Surgery Video-AssistedMediastinumPancoast SyndromePleural cavityLength of StayMiddle Agedmedicine.diseaseNeoadjuvant TherapySurgerySettore MED/18 - Chirurgia Generalemedicine.anatomical_structureTreatment OutcomeItalyThoracotomyCardiothoracic surgeryChemotherapy AdjuvantLymph Node ExcisionSurgeryFemaleRadiotherapy AdjuvantRadiologyLung cancerCardiology and Cardiovascular Medicinebusiness
researchProduct

Therapiemonitoring mittels 2-[18F]-FDG-Positronenemissionstomographie nach neoadjuvanter Strahlenbehandlung des Mundhöhlenkarzinoms

2001

Die Kombination strahlentherapeutischer und chirurgischer Behandlungsschritte beim Mundhohlenkarzinom erfordert eine fruhe, objektive Bewertung des Bestrahlungserfolgs. Schlechtes radiotherapeutisches Ansprechverhalten verlangt die moglichst umgehende chirurgische Sanierung auch bei hohem Operations- und Narkoserisiko. Eine deutliche Remission unter Strahlentherapie kann dagegen die Fortsetzung der Bestrahlungsbehandlung begrunden. Die vorliegende Studie untersucht daher die Bewertung des Bestrahlungserfolgs anhand der durch Positronenemissionstomographie (PET) bestimmten Glukosestoffwechselaktivitat.

Radiation therapyOncologyEpidermoid carcinomabusiness.industryNeoadjuvant treatmentmedicine.medical_treatmentmedicineRadiology Nuclear Medicine and imagingNuclear medicinebusinessOral cavityStrahlentherapie und Onkologie
researchProduct

Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4

2007

Ines Gockel†, Carl C Schimanski, Markus Moehler & Theodor Junginger †Author for correspondence Johannes GutenbergUniversity of Mainz, Department of General and Abdominal Surgery, Langenbeckstr. 1, 55131 Mainz, Germany Tel.: +49 6131 177 291; Fax: +49 6131 176 630; gockel@ach.klinik.unimainz.de ‘The interaction between esophageal cancer-expressed CXCR4 and SDF-1α may have a key role in directing malignant cells to ‘homing’ organs ... thus, this mechanism may account for metastasis.’

Receptors CXCR4Cancer ResearchEsophageal Neoplasmsbusiness.industryAntineoplastic AgentsGeneral MedicineEsophageal cancermedicine.diseaseCXCR4Chemokine CXCL12Cyclin-Dependent KinasesNeoadjuvant TherapyhumanitiesChemokine receptorDrug Delivery SystemsOncologyCancer researchmedicineHumansMalignant cellsbusinessChemokines CXCHoming (hematopoietic)Future Oncology
researchProduct

18F-FDG PET imaging of breast cancer : evaluation of the metabolic behaviour of the different breast cancer subtypes and prediction of the tumor resp…

2015

Positron Emission Tomography (PET) with 18Fluoro-deoxyglucose (18F-FDG) is the reference imaging examination for in-vivo quantification of the glucidic metabolism of tumour cells. It allows for the monitoring of tumour metabolic changes during chemotherapy. Breast cancer comprises several distinct genomic entities with different biological characteristics and clinical behaviours, leading to different tailored treatments. The aim of this doctoral thesis was to evaluate the relationship between the different biological entities of breast cancer and the tumour metabolic behaviour during neoadjuvant chemotherapy. We have also retrieved, among the various metabolic parameters on PET images, the …

Subtypes[SDV.IB] Life Sciences [q-bio]/BioengineeringFDGPositon EmissionTomographyRéponse tumoraleNeoadjuvant chemotherapyPhénotypesPETBreast cancerTEP[SDV.CAN] Life Sciences [q-bio]/CancerÉvaluationTomographie par Emission de PositonChimiothérapie néoadjucanteTumor responseCancer du sein[SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing
researchProduct

Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives.

2020

Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy and its incidence has been shown to increase significantly during the past decades. Complete surgical resection is currently acknowledged as the only curative treatment option able to provide adequate long-term outcomes. We herein review technical, functional and oncologic limitations for resectability, discuss current surgical aspects as well as highlight the fields in which future research and practice should focus on in order to ameliorate long-term outcomes in patients with iCCA.

Surgical resectionmedicine.medical_specialty030230 surgeryResectionBile duct cancerCholangiocarcinomaNeoplasms Multiple Primary03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHepatic InsufficiencyHumansIn patientNeoplasm InvasivenessIntensive care medicineIntrahepatic Cholangiocarcinomabusiness.industryMargins of ExcisionGeneral Medicinemedicine.diseaseHepatic malignancyNeoadjuvant TherapyLiver TransplantationBile Ducts IntrahepaticOncologyBile Duct NeoplasmsCurative treatment030220 oncology & carcinogenesisBlood VesselsLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct

Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer

2012

Objective: The aim of this study is to assess our results of treatment of women with stage I cervical cancer > 2 cm in diameter seeking fertility preservation. Treatment consisted of Laparoscopic Pelvic and Paraaortic Lymphadenectomy (LPPLND), and when no nodal metastasis was detected, neoadjuvant chemotherapy (NACT) followed by radical vaginal trachelectomy (RVT). Patients with positive lymph nodes underwent primary chemoradiation. Methods: A cohort of women younger than 40 years of age with stage I disease > 2 cm who underwent LPPLND and either NACT and RVT or chemoradiation. Oncological outcome was evaluated prospectively. Results: Eighteen women were eligible for this study. Twelve (67%…

Uterine Cervical NeoplasmRVTmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCervix UteriMetastasisParaaortic lymph nodesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesFertility preservationProspective cohort studyLymph nodeNeoadjuvant therapyCervical cancerFertility PreservationObstetrics and GynecologyChemoradiotherapyNeoadjuvant Therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantLymphatic MetastasisCarcinoma Squamous CellFemaleRadiologyHumanAdultmedicine.medical_specialtyPaclitaxelPelviRadical vaginal trachelectomyCervical carcinoma; Radical vaginal trachelectomy; Neoadjuvant chemotherapyAdenocarcinomaNeoadjuvant chemotherapyPelvisFollow-Up StudieHumansIfosfamideCervical carcinomaNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryGeneral surgeryLymphatic Metastasimedicine.diseaseProspective StudieLymph Node ExcisionLaparoscopyCisplatinNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Clinical Recommendation Radical Trachelectomy for Fertility Preservation in Patients With Early-Stage Cervical Cancer

2012

Radical trachelectomy (RT) is a fertility-sparing procedure with the aim to provide adequate oncological safety to patients with cervical cancer while preserving their fertility. In the current review, indications, development of the procedure, technical aspects, preoperative and postoperative management, and oncological, fertility, and obstetric outcomes are discussed and studied with respect to whether the procedure is performed abdominally or vaginally. Complications of RT, staging, and more conservative alternatives to RT are discussed as well. A systematic MEDLINE search was performed, which yielded 218 articles, of which 75 were selected for further analysis based on the number of pat…

Uterine Cervical Neoplasmmedicine.medical_specialtyCervical cancer; Radical trachelectomy; Fertility preservationPrognosimedia_common.quotation_subjectmedicine.medical_treatmentUterine Cervical NeoplasmsTrachelectomyFertilityHysterectomyNeoadjuvant chemotherapyRadical trachelectomy03 medical and health sciences0302 clinical medicineAbdominal radical trachelectomymedicineHumansFertility preservationStage (cooking)CervixNeoadjuvant therapyOutcomeNeoplasm Stagingmedia_commonCervical cancerVaginal radical trachelectomy030219 obstetrics & reproductive medicineHysterectomybusiness.industryGeneral surgeryFertility PreservationObstetrics and GynecologyPrognosismedicine.diseaseNeoadjuvant Therapy3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCervical cancerLymph Node ExcisionFemalebusinessHumanInternational Journal of Gynecological Cancer
researchProduct

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

2020

INTRODUCTION: Pancreatic cancer (PC), even in the absence of metastatic disease, has a dismal prognosis. One-third of them are borderline resectable (BRPC) or locally advanced unresectable PC (LAUPC) at diagnosis. There are limited prospective data supporting the best approach on these tumours. Neoadjuvant chemotherapy (ChT) is being increasingly used in this setting. METHODS: This is a retrospective series of consecutive patients staged as BRPC or LAUPC after discussion in the multidisciplinary board (MDB) at an academic centre. All received neoadjuvant ChT, followed by chemoradiation (ChRT) in some cases, and those achieving enough downstaging had a curative-intent surgery. Descriptive da…

borderline resectableCancer Researchmedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentpancreatic cancerNeutropeniaAdenocarcinomalcsh:RC254-282Pancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective Studies1506Neoadjuvant therapyRetrospective StudiesOriginal ResearchChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslocally advanced unresectableNeoadjuvant TherapyOxaliplatinSurgeryIrinotecanPancreatic NeoplasmsFOLFIRINOXOncologyFluorouracilbusinessmedicine.drugESMO open
researchProduct